🎉 Gate Square’s "Spark Program" Surpasses 1,000 KOLs!
💥 The creator ecosystem is in full bloom!
📈 Get featured, earn rewards, and grow your influence—what are you waiting for?
💰 Cash incentives ✔️
🚀 Traffic support ✔️
👑 Exclusive verification ✔️
From 0 to 1,000 in just weeks—Gate Square is becoming the epicenter of Web3 content! ⚡
You’re not just posting content, but the next "viral opportunity"!
🌟 Join the Spark Program and kickstart your breakthrough!
👉 https://www.gate.com/announcements/article/45695
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a "buy" rating.